Akebia Therapeutics (AKBA) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 1.9% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -91.9% for IMUX. Immunic is the larger company by market cap ($111.0 million vs $107.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | IMUX |
|---|---|---|
| Share price | $0.3855 | $6.99 |
| Market cap | $107.04M | $111.01M |
| 1-day change | -8.71% | -5.41% |
| YTD return | -76.06% | +30.90% |
| 1-year return | -75.13% | +1.90% |
| 5-year return | -85.56% | -91.88% |
| EPS (TTM) | $-0.17 | $-3.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | — |
| Revenue growth (YoY) | +47.46% | — |
| Net income (latest FY) | $-5.34M | $-97.17M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | — |
| Net margin | -2.26% | — |
| 52-week high | $1.73 | $17.43 |
| 52-week low | $0.361 | $5.06 |
| Distance from 52-week high | -77.72% | -59.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +678.21% | +508.73% |
| Average volume | 8.05M | 343.44K |
| Shares outstanding | 277.66M | 15.88M |
| Employees | 194 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed AKBA by 77.0 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
AKBA vs IMUX FAQ
Which is bigger, Akebia Therapeutics or Immunic?
Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $107.04M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or IMUX?
IMUX returned +1.90% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.